Coronary artery bypass grafting. A model for the understanding of the progression of atherosclerotic disease and the role of pharmacological intervention.
Fuster
V
V
Chesebro
J H
JH
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002455:Cell Division; D003094:Collagen / Q000096:biosynthesis; D001026:Coronary Artery Bypass; D004176:Dipyridamole / Q000627:therapeutic use; D004549:Elastin / Q000378:metabolism; D004727:Endothelium / Q000378:metabolism; D006083:Graft Occlusion, Vascular / Q000188:drug therapy; D006439:Hemodynamics; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D008955:Models, Cardiovascular; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D012306:Risk; D012501:Saphenous Vein; D013927:Thrombosis / Q000209:etiology
D008074:Lipoproteins; D004176:Dipyridamole; D003094:Collagen; D004549:Elastin; D001241:Aspirin